Haixi Pharmaceutical announced that HX9428, an innovative drug independently developed by the company, has been granted fast-track status by the US FDA to treat neovasculatory age-related macular degeneration. This qualification helps the company to communicate more closely with the FDA on clinical development and advance the global clinical development process. At present, HX9428 has successfully completed phase I clinical research in China, and phase II research is being carried out; overseas, it has been approved by the FDA to conduct phase II clinical trials in the US.

Haixi Pharmaceutical announced that HX9428, an innovative drug independently developed by the company, has been granted fast-track status by the US FDA to treat neovasculatory age-related macular degeneration. This qualification helps the company to communicate more closely with the FDA on clinical development and advance the global clinical development process. At present, HX9428 has successfully completed phase I clinical research in China, and phase II research is being carried out; overseas, it has been approved by the FDA to conduct phase II clinical trials in the US.